Odaia nabs $25m in Threshold and Monograph-led Series B round

• New investor Wittington Ventures also joined the round, with participation from existing investors Flint Capital, BDC Capital, StandUp Ventures and Graphite Ventures
• Emily Melton, managing partner of Threshold and Charles Conn, co-founder and partner of Monograph, will join Odaia’s board
• Odaia is the developer of MAPTUAL, a SaaS platform that leverages AI to streamline and automate the prospecting, qualifying and engagement of healthcare providers

Odaia, a Toronto-based provider of automated commercial predictive insights to pharmaceutical companies, has secured $25 million in Series B financing.

Threshold Ventures and Monograph Capital led the round. New investor Wittington Ventures also joined the round, with participation from existing investors Flint Capital, BDC Capital’s Women in Technology Venture Fund, StandUp Ventures and Graphite Ventures.

Emily Melton, managing partner of Threshold and Charles Conn, co-founder and partner of Monograph, will join Odaia’s board. Megan Kelly, principal of Threshold, will also join as a board observer.

Odaia is the developer of MAPTUAL, a software-as-a-service platform that leverages artificial intelligence to streamline and automate the prospecting, qualifying and engagement of healthcare providers, a process that has largely been manual, labor intensive and time consuming.

The funds raised will support the company’s expansion and growth and development of its solutions.

“Odaia’s ability to constantly ingest and update a broad mix of life sciences data and turn it into comprehensive insights in near-real-time turns pharmaceutical sales from reactive to proactive,” said Emily Melton, managing partner at Threshold Ventures, in a statement. “We’re thrilled to lead their Series B financing. Odaia helps get life changing drugs into the hands of those who need them faster and more efficiently.”